HomeAI · summaries
Storia in 4 fonti
ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
UNDER EMBARGO: Sunday May 31 7AM CST/ 8AM EST | In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant therapy in patients with early-stage RET fusion-positive lung cancer.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three years after a phase 3 flop led Takeda to withdraw…
- ·
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge…
- ·
ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. | In its 2,000-patient Proteus study,…
- ·
fiercebiotech.com
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data…
- ·
ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
UNDER EMBARGO: Sunday May 31 7AM CST/ 8AM EST | In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant…
- ·
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t…
- ·
morningstar.com
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people…
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung…
- ·
ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?
Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already
- ·
ASCO: AstraZeneca's Imfinzi, Imjudo duo shines in earlier-stage liver cancer
AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new phase 3 readout from its Emerald trial program assessing…
- ·
endpoints.news
ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma
ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries